Solara Reports Nil Deviation in Rights Issue Fund Utilization for Sep'26 Quarter
Solara Active Pharma Sciences Ltd · Others (Uncategorized) · 16 Oct 2026, 9:33 pm
Solara Reports Nil Deviation in Rights Issue Fund Utilization for Sep'26 Quarter Solara Active Pharma Sciences reported zero deviation in the utilization of its ₹446.62 crore Rights Issue proceeds for the quarter ended 30th Sep'26. Total funds deployed reached ₹442.88 crore, including ₹334.71 crore fully utilized for debt repayment/prepayment and ₹105.17 crore spent toward general corporate purposes against an allocated ₹112.24 crore. During the quarter, ₹1.25 crore was deployed (₹1.10 crore for debt reduction, ₹0.15 crore for corporate purposes). Remaining unutilized funds include ₹0.14 crore in escrow and ₹3.60 crore in the monitoring account.
Original exchange filing (PDF)
More announcements from Solara Active Pharma Sciences Ltd
- Transcript of Earnings Conference call pertaining to financial results of the Company for the quarter ended September 30, 2026 · 23 Oct 2026
- Solara Active Pharma Sciences Limited has informed the Exchange regarding the dispatch of Final Reminder -cum-Forfeiture Notice for the payment of outstanding call money to the holders .... · 18 Oct 2026
- Monitoring Agency Report for the quarter ended September 30, 2026 · 17 Oct 2026
- Audio recordings of Q2 FY27 earnings call conducted on October 16, 2026, for the quarter ended September 30, 2026 · 17 Oct 2026
- Solara Active Pharma Sciences Limited has informed the Exchange regarding grant of 470000 options under Solara Employee Stock Option Plan 2024 · 16 Oct 2026
- Solara Active Pharma Sciences Limited has informed the Exchange regarding a Press Release dated October 16, 2026, titled "Solara''s Q2 FY 27 revenue grows 33% to INR 4,178 Mn and EBITDA .... · 16 Oct 2026
- Solara Active Pharma Sciences Limited has informed the Exchange regarding allotment of 8,300 Equity shares pursuant to exercise of ESOP options. · 16 Oct 2026
- Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter .... · 16 Oct 2026
